Getinge Group

Getinge Group, legally associated with Getinge AB, is a Swedish medical-technology company whose products are used in hospitals, intensive-care units, operating rooms, sterilization departments, and life-science manufacturing environments. The company began in 1904 in the Swedish town of Getinge as an agricultural enterprise founded by Olander Larsson. During the 1930s it expanded into medical technology, creating the basis for the healthcare-focused business that later developed through acquisitions and organizational changes. The modern group operates through three principal business areas: Life Science, Acute Care Therapies, and Surgical Workflows. Life Science supplies equipment and systems used in pharmaceutical, biotechnology, and laboratory production environments. Acute Care Therapies addresses critical-care and intensive-care needs, including ventilators and related technologies. Surgical Workflows covers equipment and infrastructure used before, during, and after surgery, including operating-room systems, sterilization, and infection-prevention solutions. The portfolio is aimed primarily at institutional customers rather than consumers, and the business is commonly positioned around improving clinical workflows, patient care, infection control, and the efficiency of healthcare and life-science operations. Getinge became part of Electrolux in 1964 and was subsequently strengthened through acquisitions. In 1989, former Electrolux managers Rune Andersson and Carl Bennet acquired the company. Getinge was taken public in 1993 in a transaction valued at approximately SEK 600 million. Carl Bennet has remained the dominant shareholder through Carl Bennet AB, holding a substantial proportion of the capital and a majority of the voting rights according to the referenced company history. Getinge was included in the OMXS30 index from July 2009 through June 2025. Acquisitions have been central to the group’s development. Notable transactions include the purchase of Maquet GmbH in 2000, Heraeus Med in 2002, Huntleigh Technology in 2007, Atrium Medical in 2011, and Pulsion Medical Systems in 2014. More recent expansion included Healthmark Industries in 2023 and Paragonix Technologies in 2024. These transactions broadened Getinge’s presence in surgical workflows, infection prevention, cardiovascular and critical-care applications, and adjacent medical technologies. The United States is Getinge’s most important market, representing approximately 40 percent of sales in the referenced description, partly because prices and margins are higher there than in many other regions. China and Western European countries are also significant markets. The group employs approximately 12,000 people worldwide. Mattias Perjos serves as chief executive officer and Johan Malmquist as chair of the board in the referenced material. Getinge has also faced regulatory and legal challenges. The United States Food and Drug Administration ordered recalls involving two Getinge products in 2023 because of identified risks. The company has additionally reached settlements relating to alleged defects in surgical products in the United States and alleged unfair competition in Brazil. These matters illustrate the regulatory exposure associated with supplying safety-critical hospital equipment. In 2025, Getinge expanded its Servo-c ventilator offering to neonatal care, with a design intended to support preterm infants weighing as little as 500 grams.

Getinge’s origins date to 1904, when Olander Larsson established an agricultural company in Getinge, Sweden. The business moved into medical technology during the 1930s, beginning a long transition from agricultural machinery and equipment toward healthcare products. In 1964, Electrolux acquired the company. Under Electrolux ownership, Getinge was developed and expanded, including through acquisitions that increased its reach in medical technology. A decisive change came in 1989, when former Electrolux managers Rune Andersson and Carl Bennet acquired Getinge. Their ownership provided the foundation for the independently controlled group that later became one of Sweden’s significant medical-technology companies. Getinge was listed on the Stockholm Stock Exchange in 1993 in a transaction valued at approximately SEK 600 million. Carl Bennet subsequently became the company’s principal owner through Carl Bennet AB. The company was included in the OMXS30 index from July 2009 until June 2025. Growth after the listing relied heavily on acquisitions. Getinge purchased the German company Maquet GmbH in 2000, adding important surgical and hospital-equipment capabilities. Heraeus Med followed in 2002, while the acquisition of Huntleigh Technology in 2007 expanded the group’s medical-technology activities. In 2011, Getinge acquired the United States company Atrium Medical. The 2014 purchase of German company Pulsion Medical Systems further broadened its critical-care and monitoring-related portfolio. More recent transactions included Healthmark Industries in 2023 and Paragonix Technologies in 2024, continuing the group’s strategy of building a broader healthcare-technology platform. The group is organized around Life Science, Acute Care Therapies, and Surgical Workflows. This structure reflects the company’s two principal customer environments: healthcare delivery and regulated life-science production. Acute Care Therapies includes technologies for intensive and critical care, including ventilators. Surgical Workflows encompasses technologies and systems used in operating rooms, sterilization, and related hospital processes. Life Science serves pharmaceutical, biotechnology, and laboratory users. Getinge’s business is international, with the United States described as its largest market and accounting for around 40 percent of sales. China and Western Europe are also important regions. The company employs approximately 12,000 people worldwide. Its international scale exposes it to complex medical-device regulation, procurement systems, reimbursement conditions, and product-liability requirements. The company’s history has included substantial legal and regulatory scrutiny. In 2023, the United States Food and Drug Administration ordered recalls involving two Getinge products because of significant risks. Getinge also agreed to a United States settlement of approximately SEK 200 million concerning a class-action lawsuit over alleged defects in surgical products. In Brazil, the company agreed to a settlement of approximately SEK 360 million following allegations of unfair competition relating to the period from 2004 to 2017. In 2025, Getinge expanded the Servo-c ventilator platform for neonatal use. The new design was described as capable of supporting preterm infants weighing as little as 500 grams, extending the company’s acute-care portfolio into a particularly specialized and safety-sensitive patient population.

• 2025

  Servo-c neonatal expansion

  [1]Getinge Groupen.wikipedia.org

  Getinge expanded Servo-c ventilator use to neonatal patients, including very-low-weight preterm infants.

• 2024

  Acquisition of Paragonix Technologies

  [1]Getinge Groupen.wikipedia.org

  Getinge acquired United States medical-technology company Paragonix Technologies.

• 2023

  Acquisition of Healthmark Industries

  [1]Getinge Groupen.wikipedia.org

  Getinge acquired Healthmark Industries in the United States.

• 2014

  Acquisition of Pulsion Medical Systems

  [1]Getinge Groupen.wikipedia.org

  The acquisition of German company Pulsion Medical Systems strengthened Getinge’s critical-care and medical-technology activities.

• 2011

  Acquisition of Atrium Medical

  [1]Getinge Groupen.wikipedia.org

  Getinge acquired the United States company Atrium Medical.

• 2007

  Acquisition of Huntleigh Technology

  [1]Getinge Groupen.wikipedia.org

  The purchase of Huntleigh Technology PLC broadened the group’s healthcare product portfolio.

• 2002

  Acquisition of Heraeus Med

  [1]Getinge Groupen.wikipedia.org

  Getinge acquired Heraeus Med as part of its continuing expansion through medical-technology acquisitions.

• 2000

  Acquisition of Maquet GmbH

  [1]Getinge Groupen.wikipedia.org

  The acquisition of German medical-technology company Maquet expanded Getinge’s surgical and hospital-equipment capabilities.

• 1993

  Stock-market listing

  [1]Getinge Groupen.wikipedia.org

  Getinge became publicly listed in Stockholm in a transaction valued at approximately SEK 600 million.

• 1989

  Acquired by Rune Andersson and Carl Bennet

  [1]Getinge Groupen.wikipedia.org

  Former Electrolux managers Rune Andersson and Carl Bennet acquired the company.

• 1964

  Acquired by Electrolux

  [1]Getinge Groupen.wikipedia.org

  Electrolux acquired Getinge and subsequently supported its development through further acquisitions.

• 1930

  Expansion into medical technology

  [1]Getinge Groupen.wikipedia.org

  The company began expanding from agricultural activities into medical technology during the 1930s.

• 1904

  Company founded in Getinge, Sweden

  [1]Getinge Groupen.wikipedia.org

  Olander Larsson founded the original agricultural company in the Swedish town of Getinge.

A global business-to-business medical-technology supplier focused on acute care, surgical workflows, infection prevention, and life-science production. Getinge positions its portfolio as infrastructure and clinical technology for hospitals and regulated life-science organizations rather than as a consumer medical brand.

• Acute care and neonatal ventilation

  Servo ventilators

  The Servo platform is Getinge’s ventilator family for intensive and acute care. The products are intended for mechanically supporting patients whose breathing requires clinical assistance. In 2025, Getinge expanded Servo-c use to neonatal care, with the referenced design intended to support preterm infants weighing as little as 500 grams. Specific model availability and regulatory indications vary by market.

• Operating-room and surgical infrastructure

  Surgical Workflow systems

  Getinge’s Surgical Workflows portfolio covers equipment and systems intended to connect operating-room activities with broader hospital processes. The area includes technologies associated with surgical environments, operating-room infrastructure, and workflow coordination. The portfolio was materially strengthened by the company’s acquisition of Maquet and other medical-technology businesses.

• Hospital hygiene and sterile processing

  Sterilization and infection-prevention solutions

  These products support hospitals in cleaning, sterilizing, and managing reusable medical instruments and related workflows. They are used by sterile-processing and infection-prevention teams rather than by consumers. The area is connected to Getinge’s hospital-systems activities and was further developed through acquisitions including Healthmark Industries.

• Pharmaceutical and biotechnology manufacturing

  Life Science equipment and systems

  The Life Science business supplies equipment and systems for pharmaceutical, biotechnology, laboratory, and other regulated production environments. Its role is to support controlled processing and manufacturing workflows where sterility, repeatability, and regulatory compliance are important. The referenced material does not identify individual product models.

• Critical-care medical technology

  Acute Care Therapies portfolio

  Acute Care Therapies brings together technologies used in intensive-care and other high-acuity clinical settings. Ventilators are a prominent part of the portfolio, alongside related technologies acquired or developed for critical-care environments. Products are sold to healthcare institutions and are subject to market-specific medical-device regulation.

• 2023

  United States product recalls

  The United States Food and Drug Administration ordered recalls involving two Getinge products because of significant risks. The available reference does not identify the product names or provide further technical details.

  Source

• 2021

  Getinge enters settlement in U.S. mesh litigation

  Getinge entered into a settlement agreement related to the MDL mesh litigation and made an additional SEK 600 million provision. The source says the settlement was expected to become final and payment to be made during the first half of 2022.

  Source

• United States surgical-product class-action settlement

  Getinge agreed to pay approximately SEK 200 million to settle a United States class-action lawsuit concerning alleged defects in surgical products. The available reference does not provide the settlement date or identify the specific products.

  Source

• Brazilian unfair-competition settlement

  Getinge agreed to a settlement of approximately SEK 360 million with Brazilian authorities following allegations of unfair competition relating to conduct between 2004 and 2017.

  Source

Read more

• 2025

  Expansion of Servo-c into neonatal careProduct launch

  Background

  Neonatal ventilation requires equipment designed for extremely small and vulnerable patients.

  Action taken

  Getinge expanded its Servo-c ventilator offering to neonatal patients, including preterm infants weighing approximately 500 grams.

  Aftermath

  The move extended the Servo platform into a more specialized acute-care segment.

  Source

• 2024

  Acquisition of Paragonix TechnologiesM&A

  Background

  Getinge used acquisitions to extend its United States medical-technology presence.

  Action taken

  The company acquired Paragonix Technologies.

  Aftermath

  Paragonix became part of Getinge’s broader healthcare-technology portfolio.

  Source

• 2023

  Acquisition of Healthmark IndustriesM&A

  Background

  Getinge continued expanding in the United States and in hospital infection-prevention workflows.

  Action taken

  The group acquired Healthmark Industries.

  Aftermath

  The transaction broadened Getinge’s United States healthcare portfolio.

  Source

• 2000

  Acquisition of Maquet GmbHM&A

  Background

  Getinge pursued acquisitions to broaden its medical-technology portfolio and international reach.

  Action taken

  The group acquired German company Maquet GmbH.

  Aftermath

  Maquet became an important contributor to Getinge’s surgical and hospital-equipment activities.

  Source

• 1993

  Stockholm public listingStrategy

  Background

  Following the 1989 ownership change, Getinge sought access to public capital and a broader shareholder base.

  Action taken

  The company listed on the Stockholm Stock Exchange in a transaction valued at approximately SEK 600 million.

  Aftermath

  The listing provided the corporate platform for continued acquisition-led development.

  Transaction value. SEK 600 million (1993)

  Source

• 1989

  Return to independent ownershipStrategy

  Background

  After a period under Electrolux ownership, former Electrolux managers Rune Andersson and Carl Bennet acquired Getinge.

  Action taken

  The buyers established a new ownership structure that later supported independent expansion and public listing.

  Aftermath

  Carl Bennet remained the principal owner through Carl Bennet AB, while the group expanded through acquisitions and international operations.

  Source

• 2021.12.23

  Reported2021.12.23

  Getinge acquires Talis Clinical[3]Getinge 收购 Talis Clinicalprnewswire.com

  Getinge announced the acquisition of all equity interest in Talis Clinical, a US-based provider of cloud-based software solutions, and said it had paid SEK 596 million for the interest at the time of the acquisition.

• 2021.12.08

  Reported2021.12.08

  Getinge enters settlement in U.S. mesh litigation[2]Getinge enters settlement in U.S. mesh litigationfinanznachrichten.de

  Getinge entered into a settlement agreement related to the MDL mesh litigation and made an additional SEK 600 million provision. The source says the settlement was expected to become final and payment to be made during the first half of 2022.

Read more

1. 1Getinge Groupen.wikipedia.org
2. 2Getinge enters settlement in U.S. mesh litigationfinanznachrichten.de
3. 3Getinge 收购 Talis Clinicalprnewswire.com